Build an AI-Native Oncology Drug-Discovery Platform

1. 1

   Build the proprietary data and lab-automation engine

   The model is built around massive proprietary biological data (often high-content cellular imaging) generated by automated robotic wet labs, on which computer vision and machine learning find targets and design molecules. As context, Recursion has applied computer vision over 50-plus petabytes of biological data. This data-and-robotics flywheel, not any single algorithm, is the platform's core asset.

2. 2

   Apply AI to targets and molecule design

   The AI identifies novel oncology drug targets and designs optimized molecules, aiming to reduce the roughly 90 percent failure rate that plagues traditional drug discovery. The promise is finding better candidates faster. Whether AI actually improves clinical success is still being proven, so claims must stay grounded.

3. 3

   Raise very large, patient capital

   Between data infrastructure, robotics, and eventually clinical trials, this is among the most capital-intensive models anywhere, funded by large venture rounds, pharma partnerships, and public markets. Runway spans years before validation. Undercapitalization is fatal, and even well-funded platforms face brutal odds.

4. 4

   Monetize through partnerships and pipeline

   Revenue comes from pharma partnership deals and licensing (selling the platform's discoveries) and from advancing an owned oncology pipeline (as Recursion does across solid tumors, lymphoma, and B-cell malignancies). Partnerships fund the platform while the owned pipeline holds the biggest upside. Balance near-term partnership revenue against long-term pipeline bets.

5. 5

   Accept the binary clinical reality

   However good the discovery engine, candidates still must survive multi-phase clinical trials, and outcomes are binary: a program either works or it does not. Long validation timelines and trial risk sit under every projection. The card states plainly that most programs fail, and no AI removes that risk entirely.

6. 6

   Prove the platform beats traditional discovery

   The entire thesis rests on the AI-native approach outperforming conventional discovery on speed, cost, or success rate, which the field is still working to demonstrate at clinical scale. Track and communicate real evidence, not just data volume. This proof, over time, is what justifies the enormous capital the model requires.

Do not take our word for the money. Put your own numbers in and see what this idea has to earn before it works. Free, instant, no account needed.

Best for: Deeply funded scientist-founders combining AI, biology, and lab automation

Not for: Anyone without access to enormous capital and tolerance for binary, long-horizon risk. This is the highest-risk AI model in the file, and most drug programs fail. It is not for near-term returns. Nothing here is investment advice.